Biomedical subjects

L Tamarkin

Publications and source records attributed to L Tamarkin.

75 records · Page 5Linked to original sources

PubMedDate not supplied

Pulsatility of 24-hour concentrations of circulating interleukin-1-alpha in healthy women: analysis of integrated basal levels, discrete pulse properties, and correlation with simultaneous interleukin-2 concentrations.

Even though it is widely known that interleukin (IL)-1 alpha acts at the local level, it is still uncertain whether IL-1 alpha is secreted into the circulation and acts at distant sites. We have tried to elucidate this by measuring 24-hour levels of total IL-1 alpha in six healthy female volunteers. Subjects had detectable and pulsatile levels of IL-1 alpha throughout the 24-hour period. The integrated 24-hour IL-1 alpha concentration was 2,367 +/- 753 min x micrograms/l (mean +/- SD), and the integrated pulsatile IL-1 alpha concentration was 553 +/- 260 (25 +/- 10% ot total integrated IL-1 alpha). The mean IL-1 alpha concentration was 1.63 +/- 0.53 micrograms/l, mean pulse frequency/24 h was 12.8 +/- 0.8, mean pulse height was 2.31 +/- 0.52 micrograms/l; mean pulse width was 80.4 +/- 2.3 min, and mean interpulse interval was 105.3 +/- 2.8 min. Total IL-1 alpha levels significantly correlated with those previously reported for IL-2 in the same samples, and IL-1 alpha pulse parameters which are concentration independent were significantly similar to those of IL-2. Furthermore, cross-correlation analysis indicated that in 83% of our subjects (5/6) there was synchronicity of IL-1 alpha and IL-2 levels. IL-1 alpha pulse parameters were in the range reported for hormones which have well-characterized pulsatility, such as growth hormone, luteinizing hormone, follicle-stimulating hormone, cortisol, beta-endorphin, and progesterone. Based on these data we speculate that a pulsatile cytokine cascade may exist in the systemic circulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

PubMedDate not supplied

Interleukin-1 alpha differentially synchronizes estrogen-dependent and estrogen-independent human breast cancer cells in the G0/G1 phase of the cell cycle.

Direct in vitro effects of IL-1 alpha on cell cycle progression of the estrogen-responsive, MCF-7, and estrogen-unresponsive, MDA-231, human breast cancer cells were investigated by flow cytometry. IL-1 alpha, at nanomolar concentrations, caused the synchronization of MCF-7, but not MDA-231, cells in the G0/G1 phase of the cell cycle. The S phase of IL-1 treated MCF-7 cells was correspondingly decreased. The IL-1 induced synchronization of MCF-7 cells was observed in the dose range of 10(-11) M to 10(-7) M and was seen as early as 6 h after the start of treatment. Furthermore, these effects were shown to be sensitive to the weak estrogen, phenol red, since the IL-1-induced shifts in G0/G1 and S phases were markedly blunted in its presence. In cell proliferation experiments, the IL-1-induced synchronization of MCF-7 cells increased the cytotoxic efficacy of the chemotherapeutic drug, 5-fluorodeoxyuracil. These data demonstrate that IL-1 by arresting the estrogen-responsive human breast cancer cells, MCF-7, in the G0/G1-phase of the cell cycle can not only directly inhibit the growth of MCF-7 cells, but also increase the efficacy of FUDR.

Breast Neoplasms↗

PubMedDate not supplied

Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo.

Direct in vitro and in vivo effects of the lymphokine, interleukin-2 (IL-2), on hormone-dependent (MCF-7) and- independent (MDA-231) human breast cancer cell proliferation were investigated. In vitro, picomolar concentrations of IL-2 directly inhibited MCF-7 cell proliferation after 12 days of culture, while nanomolar doses of IL-2 significantly stimulated MCF-7 cell growth over the same time period. In addition, micromolar concentrations of IL-2 had virtually no effect on the in vitro proliferation of MCF-7 cells. In parallel in vitro growth experiments, the hormone-independent cells, MDA-231, were not affected by IL-2 regardless of concentration. IL-2 treatment of overiectomized, estrogen-treated nude mice, burdened with MCF-7 or MDA-231 tumors, inhibited MCF-7 tumor growth, but had no effect on MDA-231 tumors. Examination of T, B and natural killer (NK) cell function in these animals indicated that the interleukin-2-mediated effect on MCF-7 cell growth in vivo is independent of the proliferative abilities of these lymphoid cells, suggesting that IL-2 may directly affect the growth of these hormone-dependent human breast cancer cells.

Adenocarcinoma↗